Geoffrey L Chupp
Overview
Explore the profile of Geoffrey L Chupp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson G, Gautam S, Chupp G
Biomedicines
. 2024 Sep;
12(9).
PMID: 39335525
This review provides an overview of evidence supporting the existence of distinct homeostatic and inflammatory eosinophil subpopulations in health and disease. Particular emphasis is placed on describing the phenotypic and...
2.
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, et al.
Adv Ther
. 2024 May;
41(7):2978-2990.
PMID: 38802635
Introduction: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks...
3.
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, et al.
J Allergy Clin Immunol
. 2024 Mar;
154(2):297-307.e13.
PMID: 38485057
Background: MUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-IL-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma. Despite this reduction in...
4.
Gautam S, Chu J, Cohen A, Kaur R, Lee S, Wilson G, et al.
Allergy
. 2023 Oct;
78(12):3274-3277.
PMID: 37874609
No abstract available.
5.
Liu Y, Zhao J, Adams T, Wang N, Schupp J, Wu W, et al.
BMC Bioinformatics
. 2023 Oct;
24(1):394.
PMID: 37858060
No abstract available.
6.
Li B, Wang Y, Wang Z, Li X, Kay S, Chupp G, et al.
ERJ Open Res
. 2023 Aug;
9(4).
PMID: 37650091
Rationale: Asthma is a complex, heterogeneous disease strongly associated with type 2 inflammation, and blood eosinophil counts guide therapeutic interventions in moderate and severe asthma. Eosinophils are leukocytes involved in...
7.
iDESC: identifying differential expression in single-cell RNA sequencing data with multiple subjects
Liu Y, Zhao J, Adams T, Wang N, Schupp J, Wu W, et al.
BMC Bioinformatics
. 2023 Aug;
24(1):318.
PMID: 37608264
Background: Single-cell RNA sequencing (scRNA-seq) technology has enabled assessment of transcriptome-wide changes at single-cell resolution. Due to the heterogeneity in environmental exposure and genetic background across subjects, subject effect contributes...
8.
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, et al.
J Allergy Clin Immunol Pract
. 2023 Jul;
11(11):3383-3390.e3.
PMID: 37454926
Background: It remains unclear whether patients with asthma and/or chronic obstructive pulmonary disease (COPD) are at increased risk for severe coronavirus disease 2019 (COVID-19). Objective: Compare in-hospital COVID-19 outcomes among...
9.
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, et al.
Allergy
. 2023 Apr;
78(8):2148-2156.
PMID: 37073882
Background: Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or...
10.
Calhoun W, Chupp G
Allergy Asthma Clin Immunol
. 2022 May;
18(1):42.
PMID: 35598022
Globally, a small proportion (5-12%) of asthma patients are estimated to have severe disease. However, severe asthma accounts for disproportionately high healthcare resource utilization. The Global Initiative for Asthma (GINA)...